Education
About Us
Working with TipRanks
Follow Us
Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
Total Valuation
Neuphoria Therapeutics has a market cap or net worth of $9.95M. The enterprise value is ―.
Market Cap$9.95M
Enterprise Value―
Share Statistics
Neuphoria Therapeutics has 2,357,613 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,357,613
Owned by Insiders37.13%
Owned by Institutions5.29%
Financial Efficiency
Neuphoria Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is >-0.01%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)>-0.01%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee2.99M
Profits Per Employee-46.20M
Employee Count8
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuphoria Therapeutics is ―. Neuphoria Therapeutics’s PEG ratio is -0.16.
PE Ratio―
PS Ratio0.48
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF0.15
Price to Operating Cash Flow0.13
PEG Ratio-0.16
Income Statement
In the last 12 months, Neuphoria Therapeutics had revenue of 23.95M and earned -565.77K in profits. Earnings per share was -0.23.
Revenue23.95M
Gross Profit22.94M
Operating Income-1.73M
Pretax Income-1.28M
Net Income-565.77K
EBITDA-268.02K
Earnings Per Share (EPS)-0.23
Cash Flow
In the last 12 months, operating cash flow was 77.87M and capital expenditures 0.00, giving a free cash flow of 77.87M billion.
Operating Cash Flow77.87M
Free Cash Flow77.87M
Free Cash Flow per Share33.03
Dividends & Yields
Neuphoria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.39
52-Week Price Change30.45%
50-Day Moving Average8.91
200-Day Moving Average7.43
Relative Strength Index (RSI)36.75
Average Volume (3m)89.21K
Important Dates
Neuphoria Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Neuphoria Therapeutics as a current ratio of 3.56, with Debt / Equity ratio of 0.68%
Current Ratio3.56
Quick Ratio3.56
Debt to Market Cap10.09
Net Debt to EBITDA52.59K
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuphoria Therapeutics has paid -716.90K in taxes.
Income Tax-716.90K
Effective Tax Rate0.56
Enterprise Valuation
Neuphoria Therapeutics EV to EBITDA ratio is 52.54K, with an EV/FCF ratio of -182.35.
EV to Sales-587.92
EV to EBITDA52.54K
EV to Free Cash Flow-182.35
EV to Operating Cash Flow-182.35
Balance Sheet
Neuphoria Therapeutics has $13.65M in cash and marketable securities with $85.21K in debt, giving a net cash position of $13.56M billion.
Cash & Marketable Securities$13.65M
Total Debt$85.21K
Net Cash$13.56M
Net Cash Per Share$5.75
Tangible Book Value Per Share$3.43K
Margins
Gross margin is 86.49%, with operating margin of -7.21%, and net profit margin of -2.36%.
Gross Margin86.49%
Operating Margin-7.21%
Pretax Margin-5.35%
Net Profit Margin-2.36%
EBITDA Margin-1.12%
EBIT Margin-5.35%
Analyst Forecast
The average price target for Neuphoria Therapeutics is $11.15, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.15
Price Target Upside155.15% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―